ALK-1

ALK-1 詳細

英語名Activin receptor-like kinase 1市販薬剤の数0
治験薬の数1ターゲットの別称EC:2.7.11.30,ACVRLK1,Activin A Receptor Type II-Like 1,Activin A Receptor, Type II-Like Kinase 1,EC 2.7.11,ALK-1,Serine/threonine-protein kinase receptor R3,TGF-B superfamily receptor type I,Activin receptor-like kinase 1,SKR3,ALK1,ACVRL1,Activin A Receptor Like Type 1,Activin A Receptor Type IL,TSR-I,EC 2.7.11.30,HHT2,ORW2,HHT
研究&開発段階Phase 2 Clinical
英語名Activin receptor-like kinase 1
ターゲットの別称EC:2.7.11.30,ACVRLK1,Activin A Receptor Type II-Like 1,Activin A Receptor, Type II-Like Kinase 1,EC 2.7.11,ALK-1,Serine/threonine-protein kinase receptor R3,TGF-B superfamily receptor type I,Activin receptor-like kinase 1,SKR3,ALK1,ACVRL1,Activin A Receptor Like Type 1,Activin A Receptor Type IL,TSR-I,EC 2.7.11.30,HHT2,ORW2,HHT
市販薬剤の数0
治験薬の数1
研究&開発段階Phase 2 Clinical

ALK-1 製品リスト

  • 属性

    Protein (1)

  • 製品ライブラリ

    オンライン (1)

  • Human (1)

  • タグ

    His Tag (1)

  • マーカー

    Unconjugated (1)

製品番号発現システム製品説明タンパク質の構造純度特性
AL1-H5228
Human
HEK293
Human ALK-1 / ACVRL1 Protein, His Tag, low endotoxin (MALS verified)
総数量1
  • 1

ALK-1バックグランド

Serine/threonine-protein kinase receptor R3 is an enzyme that in humans is encoded by the ALK1 gene. ALK1 is a receptor in the TGF beta signaling pathway. ALK1 protein is a receptor in the TGF beta signaling pathway. It plays an important role in vascular development, remodeling, and pathologic angiogenesis, play a role in stabilizing angiogenic vessels and contribute to resistance to anti-VEGF therapies, ALK1 blockade may represent an effective therapeutic opportunity complementary to the current antiangiogenic modalities in the clinic. Recently, researcher found that, ALK1-Fc inhibited BMP9-mediated Id-1 expression in human umbilical vein endothelial cells and inhibited cord formation by these cells on a Matrigel substrate, in a chick chorioallantoic membrane assay, ALK1-Fc reduced vascular endothelial growth factor-, fibroblast growth factor-, and BMP10-mediated vessel formation, and ALK1-Fc treatment reduced tumor burden in mice receiving orthotopic grafts of MCF7 mammary adenocarcinoma cells.

ALK-1分子の別称

ACVRL1,ACVRLK1,ALK-1,HHT,HHT2,ORW2,SKR3,TSR-I

治験薬に関する情報

英語名研究コード研究開発ステージ会社適応症臨床試験
AscrinvacumabPF-3446962; GT-90001; PF-3-446-962; GT-90001C; ALK-1; GT90001C; PF-03446962Phase 2 ClinicalPfizer IncCarcinoma, Hepatocellular; Colorectal Neoplasms; Liver Neoplasms; Macular Degeneration; Mesothelioma; Neoplasms; Solid tumours
詳細
  • 詳細
  • 製品リスト
  • 治験薬に関する情報
お問い合わせ

お問い合わせ
グローバル:+1 800-810-0816(Toll Free)

メールアドレス
order.jp@acrobiosystems.com

アクロバイオシステムズ株式会社
〒101-0051
東京都千代田区神田神保町1-32-8